Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Evaluation of dengue virus strains for human challenge studies.

Mammen MP, Lyons A, Innis BL, Sun W, McKinney D, Chung RC, Eckels KH, Putnak R, Kanesa-thasan N, Scherer JM, Statler J, Asher LV, Thomas SJ, Vaughn DW.

Vaccine. 2014 Mar 14;32(13):1488-94. doi: 10.1016/j.vaccine.2013.12.040. Epub 2014 Jan 24.

PMID:
24468542
2.

Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.

Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW, Gibbons RV, Fernandez S, Gunther VJ, Mammen MP Jr, Statler JD, Innis BL.

J Infect Dis. 2013 Mar 1;207(5):700-8. doi: 10.1093/infdis/jis744. Epub 2012 Dec 5.

PMID:
23225894
3.

The human dengue challenge experience at the Walter Reed Army Institute of Research.

Lyons AG.

J Infect Dis. 2014 Jun 15;209 Suppl 2:S49-55. doi: 10.1093/infdis/jiu174.

PMID:
24872396
4.

Dengue human infection models to advance dengue vaccine development.

Larsen CP, Whitehead SS, Durbin AP.

Vaccine. 2015 Dec 10;33(50):7075-82. doi: 10.1016/j.vaccine.2015.09.052. Epub 2015 Sep 28.

5.

Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.

George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE, Haller AA, Osorio JE, Eggemeyer LM, Irby-Moore S, Frey SE, Huang CY, Stinchcomb DT.

J Infect Dis. 2015 Oct 1;212(7):1032-41. doi: 10.1093/infdis/jiv179. Epub 2015 Mar 19.

6.

A genetic and pathologic study of a DENV2 clinical isolate capable of inducing encephalitis and hematological disturbances in immunocompetent mice.

Amorim JH, Pereira Bizerra RS, dos Santos Alves RP, Sbrogio-Almeida ME, Levi JE, Capurro ML, de Souza Ferreira LC.

PLoS One. 2012;7(9):e44984. doi: 10.1371/journal.pone.0044984. Epub 2012 Sep 13.

7.

Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome.

Tuiskunen A, Wahlström M, Bergström J, Buchy P, Leparc-Goffart I, Lundkvist A.

Virol J. 2011 Aug 11;8:398. doi: 10.1186/1743-422X-8-398.

8.

Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.

Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, Innis BL, Thomas SJ, Endy TP.

J Infect Dis. 2006 Jun 15;193(12):1658-65. Epub 2006 May 9.

PMID:
16703509
9.

Identifying protective dengue vaccines: guide to mastering an empirical process.

Halstead SB.

Vaccine. 2013 Sep 23;31(41):4501-7. doi: 10.1016/j.vaccine.2013.06.079. Epub 2013 Jul 26. Review.

10.

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, Gibbons RV, Zhang C, De La Barrera R, Jarman RG, Chawachalasai W, Mammen MP Jr.

Am J Trop Med Hyg. 2008 Mar;78(3):426-33.

PMID:
18337339
11.

Atypical antibody responses in dengue vaccine recipients.

Kanesa-Thasan N, Sun W, Ludwig GV, Rossi C, Putnak JR, Mangiafico JA, Innis BL, Edelman R.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):32-8. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740953
12.

Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue.

Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1309. doi: 10.1371/journal.pntd.0001309. Epub 2011 Sep 6.

13.

Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.

Sasaki T, Setthapramote C, Kurosu T, Nishimura M, Asai A, Omokoko MD, Pipattanaboon C, Pitaksajjakul P, Limkittikul K, Subchareon A, Chaichana P, Okabayashi T, Hirai I, Leaungwutiwong P, Misaki R, Fujiyama K, Ono K, Okuno Y, Ramasoota P, Ikuta K.

Antiviral Res. 2013 Jun;98(3):423-31. doi: 10.1016/j.antiviral.2013.03.018. Epub 2013 Mar 29.

PMID:
23545366
14.

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.

Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP.

Sci Transl Med. 2016 Mar 16;8(330):330ra36. doi: 10.1126/scitranslmed.aaf1517. Epub 2016 Mar 16.

PMID:
27089205
15.

[Dengue fever: from disease to vaccination].

Teyssou R.

Med Trop (Mars). 2009 Aug;69(4):333-4. French.

PMID:
19725380
16.

Determination of viremia and concentration of circulating nonstructural protein 1 in patients infected with dengue virus in Mexico.

de la Cruz-Hernández SI, Flores-Aguilar H, González-Mateos S, López-Martinez I, Alpuche-Aranda C, Ludert JE, del Angel RM.

Am J Trop Med Hyg. 2013 Mar;88(3):446-54. doi: 10.4269/ajtmh.12-0023. Epub 2013 Jan 21.

17.

Dengue virus vaccine development.

Yauch LE, Shresta S.

Adv Virus Res. 2014;88:315-72. doi: 10.1016/B978-0-12-800098-4.00007-6. Review.

PMID:
24373316
18.

Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity.

Omatsu T, Moi ML, Hirayama T, Takasaki T, Nakamura S, Tajima S, Ito M, Yoshida T, Saito A, Katakai Y, Akari H, Kurane I.

J Gen Virol. 2011 Oct;92(Pt 10):2272-80. doi: 10.1099/vir.0.031229-0. Epub 2011 Jun 22.

PMID:
21697346
19.

Production and testing of dengue virus strains suitable for human infection studies.

Eckels KH.

J Infect Dis. 2014 Jun 15;209 Suppl 2:S46-8. doi: 10.1093/infdis/jiu161.

PMID:
24872395
20.

Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models.

Tang WW, Grewal R, Shresta S.

Curr Opin Virol. 2015 Aug;13:61-6. doi: 10.1016/j.coviro.2015.04.007. Epub 2015 May 23. Review.

PMID:
26001278

Supplemental Content

Support Center